Amgen (AMGN) stocks have witnessed a significant surge and decline alongside market gains. The firm's 'Buy (B-)' rating was reaffirmed by Weiss Ratings. FDA's approval of
TEZSPIRE for CRSwNP might expand Amgen's treatment portfolio and reach. UBS also raised their price target on Amgen to $326 from $315, while Asset Management One Co. Ltd and Greatmark Investment Partners Inc substantially boosted their holdings in the company. However, Amgen's valuation is under scrutiny following a recent 6% rise in share price. The company's launch of
AmgenNow is likely to increase patient access. Furthermore, Amgen seen encouraging revenue growth and breakthroughs especially in cardiovascular studies. Their stock has attracted much attention with 81% institutional backing and the firm's sensible use of debt. The firm's potential growth is turning it into a safe bet for income investors. This is seen as they receive a $650M Puerto Rico facility expansion and successfully launch
MariTide while also forging forward with significant expansion of their
R&D efforts. On another note, Rep. Lisa C. McClain sold off her shares of Amgen. Key indicators are pointing to a possible increase in the company's earnings and Amgen's ascendance in the stock market despite market declinations. In addition, the firm recently received FDA approval for
Repatha® in cardiovascular risk management. However, drug price discounting and share buyback activities put the company in a delicate position.
Amgen AMGN News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 25 Oct 2025 20:01:45 GMT -
Rating 6
- Innovation 8
- Information 9
- Rumor 6
